ReviewFrontiers in endocrinology2026
Some cases of primary hyperparathyroidism may not be truly primary in origin.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hyperparathyroidism (PHPT) is the third most common endocrine disorder and is traditionally considered to result from intrinsic pathology. However, this traditional view is challenged by several persistent clinical and epidemiological observations. Therefore, we hypothesize that some cases of PHPT may not be truly primary in origin. Some of them may be irreversible secondary hyperparathyroidism (tertiary hyperparathyroidism), which may be initiated and perpetuated by widely existed chronic calcium and/or vitamin D insufficiency. The "primary" (in fact, irreversible secondary hyperparathyroidism or "tertiary" hyperparathyroidism) and "secondary" hyperparathyroidism states are not dichotomous but are linked through a process of chronic stimulation, adaptive hyperplasia, and eventual clonal transformation. This model is supported by epidemiological evidence demonstrating an association between low lifelong calcium intake and increased PHPT risk, physiological evidence of persistent PTH suppressibility by calcium intake, and the high rate of clinical misdiagnosis between primary and secondary hyperparathyroidism. If validated, this reframing would mandate a paradigm shift in the understanding and management of PHPT or irreversible secondary hyperparathyroidism. It emphasizes the critical need to rigorously identify and correct underlying nutritional deficiency as a fundamental diagnostic and therapeutic step, transforming the management approach from a predominantly surgical model to one focused on prevention, early medical intervention, and addressing a key modifiable environmental cause.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.